JO3446B1 - طريقة لمعالجة الأرق الأولي - Google Patents

طريقة لمعالجة الأرق الأولي

Info

Publication number
JO3446B1
JO3446B1 JOP/2002/0086A JOP20020086A JO3446B1 JO 3446 B1 JO3446 B1 JO 3446B1 JO P20020086 A JOP20020086 A JO P20020086A JO 3446 B1 JO3446 B1 JO 3446B1
Authority
JO
Jordan
Prior art keywords
melatonin
primary insomnia
treating primary
factors
insomnia
Prior art date
Application number
JOP/2002/0086A
Other languages
English (en)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11075696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3446(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals S A filed Critical Neurim Pharmaceuticals S A
Application granted granted Critical
Publication of JO3446B1 publication Critical patent/JO3446B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

يتعلق هذا الاختراع بدواء لمعالجة وتحسين النوعية المعيدة للصحة للنوم في مريض يعاني من الأرق الأولي، يشتمل على مركب واحد على الأقل يختار من ميلاتونين، عوامل مولدة للميلاتونين، عوامل تألف الميلاتونين وعوامل ضادة للملايتونين بمقدار فعال ضمن المدى من 0.0025 الى 50مجج ويجوز أن يشتمل على عامل فعال علاجيا واحد أو كثر
JOP/2002/0086A 2001-08-14 2002-08-08 طريقة لمعالجة الأرق الأولي JO3446B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL144900A IL144900A (en) 2001-08-14 2001-08-14 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Publications (1)

Publication Number Publication Date
JO3446B1 true JO3446B1 (ar) 2020-07-05

Family

ID=11075696

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2002/0086A JO3446B1 (ar) 2001-08-14 2002-08-08 طريقة لمعالجة الأرق الأولي

Country Status (35)

Country Link
US (1) US8962024B2 (ar)
EP (2) EP1441702B1 (ar)
JP (1) JP2005501095A (ar)
KR (1) KR20040032917A (ar)
CN (1) CN100453078C (ar)
AR (1) AR034975A1 (ar)
AU (1) AU2002326114C1 (ar)
BR (1) BR0211855A (ar)
CA (1) CA2454699C (ar)
CL (1) CL2002001701A1 (ar)
CR (1) CR7271A (ar)
CY (2) CY1118924T1 (ar)
DK (2) DK1441702T3 (ar)
EA (1) EA200400302A1 (ar)
ES (2) ES2882584T3 (ar)
GT (1) GT200200164A (ar)
HU (1) HU230786B1 (ar)
IL (1) IL144900A (ar)
IS (1) IS3004B (ar)
JO (1) JO3446B1 (ar)
LT (1) LT1441702T (ar)
MX (1) MXPA04001372A (ar)
NO (1) NO334788B2 (ar)
NZ (1) NZ531318A (ar)
PA (1) PA8552301A1 (ar)
PE (1) PE20030331A1 (ar)
PL (1) PL367872A1 (ar)
PT (2) PT1441702T (ar)
PY (1) PY0218122A (ar)
RU (1) RU2560840C2 (ar)
SI (1) SI1441702T1 (ar)
UA (1) UA87262C2 (ar)
UY (1) UY27401A1 (ar)
WO (1) WO2003015690A2 (ar)
ZA (1) ZA200402005B (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
JP6830156B2 (ja) 2016-10-31 2021-02-17 ニューリム・ファーマシューティカルズ・リミテッドＮｅｕｒｉｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． メラトニンミニタブレットおよびその製造方法
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378109B (ar) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (ar) 1972-05-19 1975-08-18 Bofors Ab
DE3466215D1 (en) 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ　ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707652A (en) 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5591768A (en) * 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
ES2134789T3 (es) 1991-05-09 1999-10-16 Neurim Pharma 1991 Composiciones que contienen melatonina.
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69303919T2 (de) * 1992-04-07 1997-01-30 Neurim Pharma 1991 Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IL103411A (en) 1992-10-11 1996-11-14 Neurim Pharma 1991 Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
ATE177101T1 (de) 1992-12-17 1999-03-15 Pfizer Pyrrolopyrimidine als crf antagonisten
DK0674624T3 (da) 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
KR100190730B1 (ko) 1992-12-17 1999-06-01 디. 제이. 우드, 스피겔 알렌 제이 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
WO1995003043A1 (en) 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5654325A (en) 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
NO981489L (no) * 1995-10-03 1998-05-22 Interneuron Pharma Blandinger av melatonin og analgetika samt anvendelser derav
ATE265209T1 (de) * 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5826408A (en) * 1997-05-08 1998-10-27 Riverwood International Corporation Rotary flap tucker for a cartoning machine
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
MXPA02005783A (es) * 2000-01-05 2003-10-14 Neurim Pharma 1991 Metodo y formulacion para el tratamiento de la resistencia a los antihipertensivos y otras afecciones asociadas.
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6703412B1 (en) 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
JP2014533981A (ja) 2011-09-27 2014-12-18 アイビス・メディカル・インコーポレーテッド 胃内インプラントデバイス

Also Published As

Publication number Publication date
WO2003015690A3 (en) 2003-09-25
CN1541092A (zh) 2004-10-27
ES2882584T3 (es) 2021-12-02
MXPA04001372A (es) 2005-06-06
LT1441702T (lt) 2017-06-12
GT200200164A (es) 2003-09-26
CA2454699A1 (en) 2003-02-27
CA2454699C (en) 2012-03-27
EA200400302A1 (ru) 2004-10-28
EP1441702A2 (en) 2004-08-04
JP2005501095A (ja) 2005-01-13
SI1441702T1 (sl) 2017-08-31
AR034975A1 (es) 2004-03-24
CY1124763T1 (el) 2022-07-22
IL144900A (en) 2013-12-31
NO334788B1 (no) 2014-05-26
AU2002326114A1 (en) 2003-03-03
EP1441702B1 (en) 2017-05-10
CL2002001701A1 (es) 2010-06-25
EP3103443B1 (en) 2021-06-30
AU2002326114B2 (en) 2007-03-08
HUP0401042A2 (hu) 2004-08-30
UY27401A1 (es) 2003-02-28
HK1066161A1 (zh) 2005-03-18
AU2002326114C1 (en) 2019-03-21
PL367872A1 (en) 2005-03-07
PA8552301A1 (es) 2003-06-30
NO334788B2 (no) 2014-05-26
US8962024B2 (en) 2015-02-24
CY1118924T1 (el) 2018-01-10
NO20040087L (no) 2004-02-19
HUP0401042A3 (en) 2009-07-28
EP3103443A1 (en) 2016-12-14
PE20030331A1 (es) 2003-06-27
DK3103443T3 (da) 2021-08-30
DK1441702T3 (en) 2017-06-06
IS3004B (is) 2018-09-15
UA87262C2 (uk) 2009-07-10
KR20040032917A (ko) 2004-04-17
NZ531318A (en) 2005-08-26
IL144900A0 (en) 2002-06-30
PY0218122A (es) 2004-03-01
ES2626591T3 (es) 2017-07-25
IS7136A (is) 2004-01-30
CR7271A (es) 2004-05-17
EP1441702A4 (en) 2007-09-26
RU2011131532A (ru) 2013-03-27
PT3103443T (pt) 2021-08-12
US20040248966A1 (en) 2004-12-09
PT1441702T (pt) 2017-06-02
RU2560840C2 (ru) 2015-08-20
BR0211855A (pt) 2004-09-21
WO2003015690A2 (en) 2003-02-27
ZA200402005B (en) 2005-07-27
WO2003015690B1 (en) 2004-03-11
HU230786B1 (en) 2018-05-02
CN100453078C (zh) 2009-01-21

Similar Documents

Publication Publication Date Title
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
GB0223040D0 (en) Therapeutic compounds
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
IL149134A0 (en) Pharmaceutical compositions containing tofisopam
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
GB0020504D0 (en) Therapeutic method
EA200501666A1 (ru) Композиция для улучшения познавательной способности и памяти
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
AP1896A (en) The method of treating cancer
MY130725A (en) Composition and method for treating allergic diseases
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
NO984198L (no) FremgangsmÕte for behandling av aggresjon
SE9803623D0 (sv) New therapeutic application
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії